Crossject | ALCJ FP | Supergenerics | France | Updates

This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

Crossject ^CR	Bloomberg ALCJ FP
Supergenerics / France	Web Site \| Investors Relation

Still some way to go...

Target

Upside 240%

Price (€) 3.36

Target Price (€) 11.4

Market Cap (€M) 122

Perf. 1W:	-1.03%
Perf. 1M:	1.97%
Perf. 3M:	-28.2%
Perf Ytd:	1.97%

10 day relative perf. to stoxx600:	1.13%
20 day relative perf. to stoxx600:	0.68%

EPS change18/08/2021

Download

Change in EPS	2021 : € 0.18 vs 0.18	-0.32%
	2022 : € 0.91 vs 0.91	-0.32%
We have only integrated the detailed numbers for FY20, which translate into a slightly lower EPS. However, the change is not meaningful given the still very low level of results of the company before its products reach the market.

17 Dec 21 Financing issue
New financing

24 Sep 21 Earnings/sales releases
H1 21: unsurprising (as usual)

31 Aug 21 EPS change
We have fine-tuned our numbers on the back of...

18 Aug 21 EPS change
We have only integrated the detailed numbers f...

18 Jun 21 Latest
Another good piece of news for the group

17 Jun 21 Latest
A licensing agreement for Zeneo Hydrocortison...

31 Mar 21 Earnings/sales releases
FY20 unsuprising; waiting for more

15 Dec 20 Financing issue
A double bond issue

21 Sep 20 Earnings/sales releases
Update on the group's business

22 May 20 EPS change
No major changes after the release of the FY19...